Stocks · News reference
Sight Sciences (NASDAQ:SGHT) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.15) by 46.67 percent. This is a 65.22 percent increase over losses of $(0.23) per share from
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Indications for Use state:"The Sight Sciences TearCare System is a thermal-activated gland expression therapy that improves meibomian gland function in adult patients with evaporative dry eye disease due to
Filed: 2026-08-10 AccNo: 0001193125-26-341346 Size: 170 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
UBS analyst Patrick Wood maintains Sight Sciences (NASDAQ:SGHT) with a Buy and raises the price target from $7 to $8.
Sight Sciences (NASDAQ:SGHT) raises FY2026 sales outlook from $83.000 million-$89.000 million to $88.000 million-$92.000 million vs $86.083 million estimate.